Log in

NASDAQ:TRIB - Trinity Biotech Stock Price, Forecast & News

+0.01 (+1.02 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: $1.00
50-Day Range
MA: $0.91
52-Week Range
Now: $1.00
Volume25,732 shs
Average Volume66,468 shs
Market Capitalization$23.93 million
P/E RatioN/A
Dividend YieldN/A
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:TRIB



Sales & Book Value

Annual Sales$97.04 million
Cash Flow$0.27 per share
Book Value$1.83 per share


Net Income$-22,090,000.00


Market Cap$23.93 million
Next Earnings Date3/5/2020 (Estimated)

Receive TRIB News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) announced its quarterly earnings data on Wednesday, October, 16th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.06 by $0.02. The business had revenue of $24.59 million for the quarter. Trinity Biotech had a negative net margin of 31.56% and a negative return on equity of 10.96%. View Trinity Biotech's Earnings History.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Trinity Biotech.

Has Trinity Biotech been receiving favorable news coverage?

Press coverage about TRIB stock has been trending positive on Saturday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trinity Biotech earned a news impact score of 3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Trinity Biotech.

Who are some of Trinity Biotech's key competitors?

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Netflix (NFLX), QUALCOMM (QCOM), Celgene (CELG), Gilead Sciences (GILD), Expedia Group (EXPE), Illumina (ILMN), Nightstar Therapeutics (NITE), Novavax (NVAX), Opko Health (OPK) and Supernus Pharmaceuticals (SUPN).

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the folowing people:
  • Mr. Ronan O'Caoimh, Co-Founder, Chairman & CEO (Age 63)
  • Mr. Kevin Tansley, CFO, Company Sec. & Exec. Director (Age 48)
  • Dr. James Walsh, Exec. Director (Age 61)

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a number of of retail and institutional investors. Top institutional investors include Adirondack Research & Management Inc. (1.73%) and Millennium Management LLC (0.64%).

Which major investors are selling Trinity Biotech stock?

TRIB stock was sold by a variety of institutional investors in the last quarter, including Adirondack Research & Management Inc..

Which major investors are buying Trinity Biotech stock?

TRIB stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC.

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $1.00.

How big of a company is Trinity Biotech?

Trinity Biotech has a market capitalization of $23.93 million and generates $97.04 million in revenue each year. View Additional Information About Trinity Biotech.

What is Trinity Biotech's official website?

The official website for Trinity Biotech is http://www.trinitybiotech.com/.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]

MarketBeat Community Rating for Trinity Biotech (NASDAQ TRIB)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel